Equillium | Investor Presentation Deck | 39 slides

Equillium · 2023-11
arc beats above · slides in the middle · loops below · scroll → 2 LOOPS
SETUP TENSION ANALYSIS EVIDENCE RESOLUTION APPENDIX
HOVER FOR DETAILS · CLICK A SLIDE FOR FULLSCREEN · STEP 2
No image bound to this slide. Wire up imgproxy to display the rendered slide JPEG.

Deck intelligence map

5
coverage by narrative range · generated from this deck JSON

Slide inventory

39
every slide · same image gating as the playbook
01
Slide 1
front_matter
03
Uses a hub-and-spoke diagram to represent the company's strategic pillars.summarize
Open slide detailLoop · Golden Circle
04
The slide uses a Gantt-style visualization for drug development stages.plan_implementation
Open slide detailLoop · Golden Circle
05
This is a section divider or introductory slide for the product solution.present_solution
Open slide detailBeat · SolutionLoop · Golden Circle
06
Includes specific financial breakdown of deal value and R&D funding obligations.show_traction
Open slide detailBeat · Solution
07
The slide uses a side-by-side comparison structure to detail trial status and upcoming milestones for two distinct clinical programs.plan_implementation
Open slide detailBeat · Solution
08
transition
Open slide detailBeat · Solution
09
Includes a diagram illustrating cytokine-receptor binding and downstream signaling.establish_context
Open slide detailBeat · Solution
10
Uses a visual comparison framework to illustrate the 'Goldilocks' problem in drug development.frame_problem
Open slide detailBeat · Problem
11
The diagram uses a hub-and-spoke model to show how various scientific disciplines feed into the central 'Drug Products' core.present_solution
12
The slide uses a hub-and-spoke visual metaphor to explain the shared signaling mechanism of the γC receptor family.present_solution
13
The slide uses a process diagram to show the transition from native cytokine sequences to a proprietary composite sequence, resulting in an engineered inhibitorpresent_solution
14
The slide uses a biological mechanism diagram to illustrate how the inhibitor selectively targets specific cytokines (A, D, F) while leaving others unaffected.present_solution
15
The slide uses a visual mechanism to show how different inhibitors interact with cell signaling pathways.present_solution
16
transition
17
The slide uses a four-column structure to explain the target, the molecule, the preclinical results, and the clinical results.present_solution
18
The slide uses a column-based layout to compare four distinct disease indications.size_opportunity
Open slide detailBeat · Market Size
19
The slide uses Western blot data to visually demonstrate the efficacy of EQ101 compared to a standard JAK inhibitor.present_solution
20
Includes before/after clinical photos and a comparative table against Mogamulizumab.show_traction
Open slide detailBeat · Traction
21
show_traction
Open slide detailBeat · Traction
22
The slide uses a circular process diagram to show the feedback loop of immune cells and cytokines attacking the hair follicle.present_solution
23
Includes visual longitudinal study (Day 0, 14, 21) and a bar chart comparing efficacy against PBS and Ruxolitinib.present_solution
24
The slide compares two different drugs (baricitinib and deuruxolitinib) using two different chart types (line chart with negative values vs line chart with posicompare_peers
25
Includes a specific callout for a Blackbox warning on existing competitors.frame_problem
Open slide detailLoop · Cost Of Inaction
26
Includes a timeline-style process diagram for the study phases.plan_implementation
27
transition
28
The slide uses a four-column layout to explain the target, the molecule structure, the mechanism of action, and the current clinical status.present_solution
29
frame_problem
30
Includes a biological process diagram and a gene expression heatmap.frame_problem
31
The slide uses a biological pathway diagram and a bar chart to demonstrate efficacy.present_solution
32
The slide uses a process-like diagram to show treatment approaches and highlights the specific mechanism of action (IL-15/IL-21 inhibition) as a superior strateargue_timing
33
The slide outlines a sequential clinical trial process.plan_implementation
34
transition
35
The slide highlights the team's pedigree by listing past company affiliations for each executive and providing a collective logo grid at the bottom.other
Open slide detailBeat · Team
36
The slide uses a timeline framework to map patent coverage and exclusivity periods across two main product categories.other
37
The slide provides a snapshot of the company's financial health as of late 2023.summarize
38
The slide uses a grouped list format to present clinical trial milestones.plan_implementation
39
state_next_steps